Denali Therapeutics Inc. (DNLI) is currently priced at $20.07, showing a positive price change of 13 cents (0.652%) from the previous close of $19.94. The trading volume stands at $249,693, representing a 14.85% increase compared to the average.
The latest quarterly earnings report for DNLI, announced on Wednesday, February 25th, revealed an earnings per share of -73 cents, slightly better than the consensus estimate of -75 cents.
The company's cash flow indicates a net change in cash of $114.36 million, with free cash flow at -$100 million. Noteworthy is the issuance of common stock amounting to $192.15 million.
DNLI's income statement shows an operating income of -$137.37 million, resulting in a net income of -$128.55 million. The company reported revenue of $zero and operating expenses totaling $134.50 million.
Key financial ratios for DNLI include a quick ratio of 9.16, cash ratio of 2.09, and a debt-equity ratio of 4.17. Notably, the company's price to earnings ratio stands at -5.63, indicating a potential undervaluation.
The balance sheet reflects total assets of $1.14 billion, with significant holdings in short-term investments at $662.55 million and total investments at $763.98 million. DNLI's net debt is reported at -$163 million.
This financial snapshot of Denali Therapeutics Inc. provides insights into its current performance and financial health.